Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

134.94 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 28
Open 134.94
Bid (Size) 135.08 (1)
Ask (Size) 138.00 (1)
Prev. Close 134.94
Today's Range 134.94 - 134.94
52wk Range 110.03 - 207.59
Shares Outstanding 145,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Expectations For Biogen's Future
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga

Performance

YTD
-10.0%
-10.0%
1 Month
+5.8%
+5.8%
3 Month
+9.1%
+9.1%
6 Month
-2.5%
-2.5%
1 Year
-32.7%
-32.7%

More News

Read More
Q2 Rundown: Gilead Sciences (NASDAQ:GILD) Vs Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday?
Via Benzinga
Topics Economy
Earnings Scheduled For July 31, 2025
Via Benzinga
Biogen's Earnings Outlook
Via Benzinga
Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know
Via StockStory
Topics Economy
How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment
Via Benzinga
Exploring the top movers within the S&P500 index during today's session.
Via Chartmill
BIIB Q2 Deep Dive: New Launches Offset Legacy Pressure, Pipeline Advancements Drive Guidance
Via StockStory
Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
From Biogen Inc.
Via GlobeNewswire
Beyond The Numbers: 8 Analysts Discuss Biogen Stock
Via Benzinga
Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate
Via Benzinga
Biogen (NASDAQ:BIIB) Reports Bullish Q2
Via StockStory
Topics Artificial Intelligence
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
From Biogen Inc.
Via GlobeNewswire
Biogen Earnings: What To Look For From BIIB
Via StockStory
Topics Artificial Intelligence
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
From Biogen Inc.
Via GlobeNewswire
1 Nasdaq 100 Stock to Target This Week and 2 That Underwhelm
Via StockStory
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US
Via Benzinga
Topics Government
FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division
Via Benzinga
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025
From Biogen Inc.
Via GlobeNewswire
Biogen (BIIB) Stock Trades Down, Here Is Why
Via StockStory
Topics Lawsuit
Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing
Via Benzinga

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 134.94
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 08/14/25 04:00 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 19.67B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 20B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.